Final results from randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for HER2-negative breast cancers

被引：5
|
作者：
Zelnak, A. B.
Harichand-Herdt, S.
Styblo, T. M.
Rizzo, M.
Gabram, S. G. A.
Bumpers, H. L.
Hermann, R. C.
Srinivasiah, J.
Schnell, F. M.
O'Regan, R.
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Emory Univ, Atlanta, GA 30322 USA
[3] Emory Univ, Dept Surg, Atlanta, GA 30322 USA
[4] Emory Winship Canc Inst, Atlanta, GA USA
[5] Morehouse Univ, Atlanta, GA USA
[6] Northwest Georgia Oncol Ctr, Marietta, GA USA
[7] Georgia Ctr Oncol Res & Educ, Atlanta, GA USA
[8] Grady Mem Hosp, Georgia Canc Ctr Excellence, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.1118
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1118
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Eribulin/Cyclophosphamide versus Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer: A Randomized Phase II Trial of the Sarah Cannon Research Institute
    Yardley, D. A.
    Hainsworth, J. D.
    Shastry, M.
    Finney, L.
    Burns, H. A.
    CANCER RESEARCH, 2012, 72
  • [32] A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer
    Otto Metzger Filho
    Anita Giobbie-Hurder
    Nancy U. Lin
    Meredith Faggen
    Steven Come
    Thomas Openshaw
    Michael Constantine
    Jeanna Walsh
    Rachel A. Freedman
    Bryan Schneider
    Harold J. Burstein
    Erica L. Mayer
    Breast Cancer Research and Treatment, 2021, 185 : 135 - 144
  • [33] A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer
    Metzger Filho, Otto
    Giobbie-Hurder, Anita
    Lin, Nancy U.
    Faggen, Meredith
    Come, Steven
    Openshaw, Thomas
    Constantine, Michael
    Walsh, Jeanna
    Freedman, Rachel A.
    Schneider, Bryan
    Burstein, Harold J.
    Mayer, Erica L.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 135 - 144
  • [34] A randomized, phase 2 trial of preoperative MM-121 with paclitaxel in triple negative (TN) and hormone receptor (HR) positive, HER2-negative breast cancer
    Holmes, Frankie A.
    McIntyre, Kristi J.
    Krop, Ian E.
    Osborne, Cynthia R.
    Smith, John W., II
    Modiano, Manuel R.
    Gupta, Manish
    Downey, Leona B.
    Nanda, Rita
    Saleh, Mansoor N.
    Young, Jonathan R.
    Horgan, Kerry E.
    Kubasek, William
    MacBeath, Gavin
    Danso, Michael A.
    O'Shaughnessy, Joyce A.
    CANCER RESEARCH, 2015, 75
  • [35] Phase II study of an all-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): First results of an international phase II trial.
    Tubiana-Mathieu, N.
    Bougnoux, P.
    Becquart, D.
    Chan, A.
    Majois, F.
    Espie, M.
    Aubert, D.
    Bourlard, T.
    Villanova, G.
    Conte, P-F
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S280 - S280
  • [36] A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01)
    Hurvitz, Sara A.
    Allen, Heather J.
    Moroose, Rebecca L.
    Chan, David
    Hagenstad, Christopher
    Applebaum, Steven H.
    Patel, Giribala
    Hu, Eddie H.
    Ryba, Nancy
    Lin, Lii-Shin
    Wang, HeJing
    Glaspy, John
    Slamon, Dennis J.
    Kabbinavar, Fairooz
    CLINICAL BREAST CANCER, 2010, 10 (04) : 307 - 312
  • [37] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
    Masataka Yoshimoto
    Shintaro Takao
    Masaru Hirata
    Yasushi Okamoto
    Sumio Yamashita
    Yoshihiro Kawaguchi
    Makoto Takami
    Hidemi Furusawa
    Satoshi Morita
    Chigusa Abe
    Junichi Sakamoto
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 331 - 338
  • [38] Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
    Wardley, Andrew M.
    Pivot, Xavier
    Morales-Vasquez, Flavia
    Zetina, Luis M.
    Dias Gaui, Maria de Fatima
    Reyes, Douglas Otero
    Jassem, Jacek
    Barton, Claire
    Button, Peter
    Hersberger, Veronica
    Torres, Antonio Anton
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 976 - 983
  • [39] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
    Yoshimoto, Masataka
    Takao, Shintaro
    Hirata, Masaru
    Okamoto, Yasushi
    Yamashita, Sumio
    Kawaguchi, Yoshihiro
    Takami, Makoto
    Furusawa, Hidemi
    Morita, Satoshi
    Abe, Chigusa
    Sakamoto, Junichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 331 - 338
  • [40] Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer
    Prat, A.
    Ortega, V.
    Villagrasa, P.
    Pare, L.
    Galvan, P.
    Oliveira, M.
    Nuciforo, P.
    Lluch, A.
    Morales, S.
    Amillano, K.
    Lopez, R.
    Gonzalez, R.
    Manso, L.
    Martinez, J.
    Llombart, A.
    De la Pena, L.
    Di Cosimo, S.
    Rubio, I. T.
    Harbeck, N.
    Baselga, J.
    Cortes, J.
    CANCER RESEARCH, 2017, 77
12345